Gan & Lee(SH:603087) Xin Lang Cai Jing·2026-01-08 06:48Core Viewpoint - 甘李药业 has shown a positive financial performance with significant growth in revenue and net profit, indicating strong operational capabilities and market demand for its products [2][3]. Group 1: Stock Performance - On January 8, 甘李药业's stock price decreased by 2.04%, closing at 70.03 CNY per share, with a trading volume of 471 million CNY and a turnover rate of 1.19%, resulting in a total market capitalization of 41.83 billion CNY [1]. - Year-to-date, the stock price has increased by 2.88%, with a 4.58% rise over the last five trading days, a 10.42% increase over the last 20 days, and a 1.20% rise over the last 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, 甘李药业 reported a revenue of 3.05 billion CNY, representing a year-on-year growth of 35.73%, and a net profit attributable to shareholders of 818 million CNY, which is a 61.32% increase compared to the previous year [2]. - Since its A-share listing, 甘李药业 has distributed a total of 1.61 billion CNY in dividends, with 1.02 billion CNY distributed over the last three years [3]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for 甘李药业 reached 94,700, an increase of 22.53% from the previous period, while the average number of circulating shares per person decreased by 17.81% to 5,889 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the third largest with 8.0042 million shares, an increase of 494,300 shares from the previous period [3].